Pricing Log in Create free account
Friday 6 November 2026 Export SEPN’s income statement to Excel — free account

Septerna, Inc.

SEPN Healthcare Biotechnology

Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024.

Revenue
+22,375.6%
EPS
+48.2%
Free cash flow
−9.01%

Quarter to June 2026, against a year earlier

48.95 1.60 +3.38%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−32.6×
Dividend yield
—
F-score
5/9
Altman Z
3.41
Beneish M
32.85
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Septerna, Inc. (SEPN) Free cash flow

Alert me on Free cash flow

Septerna, Inc.'s free cash flow for fiscal 2025 was $122.2M, compared with −$46.9M in fiscal 2024. Over the twelve months to 30 June 2026 it was $117.6M. Septerna, Inc. ranks 27th of 603 Biotechnology companies by free cash flow.

Free cash flow, annual

Embed this chart

Annual newest first

Period Free cash flow Change
FY2025 $122.2M —
FY2024 −$46.9M —
FY2023 −$16.6M —

Quarterly newest first

Period Free cash flow Change
Jun 2026 −$22.2M —
Mar 2026 −$26.5M —
Dec 2025 −$15.1M —
Sep 2025 $181.3M —
8 more quarters

Free cash flow against peers

Company Free cash flow
AUPH Aurinia Pharmaceuticals Inc compare $177.0M
SEPN Septerna, Inc. $117.6M
VCEL Vericel Corporation compare $57.9M
PVLA Palvella Therapeutics, Inc. compare −$36.5M
ZYME Zymeworks Inc. compare −$120.5M
IMNM Immunome, Inc. compare −$219.1M
VERA Vera Therapeutics, Inc. compare −$338.9M
BHVN Biohaven Ltd. compare −$473.2M
LKFT Lakefront Biotherapeutics - Sponsored ADR compare −$524.5M

What Free cash flow is

Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.

Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)

The full definition of Free cash flow →

More on SEPN